Cytosolic Trapping of a Mitochondrial Heat Shock Protein Is an Early Pathological Event in Synucleinopathies by Szego EM et al.
ArticleCytosolic Trapping of a Mitochondrial Heat Shock
Protein Is an Early Pathological Event in
SynucleinopathiesGraphical AbstractHighlightsd aSyn sequesters HSP10 in the cytosol and prevents it from
acting in the mitochondria
d Overexpression of HSP10 delays aSyn pathology in vitro and
in vivo
d HSP10 modulates aSyn pathology in synaptic terminalsSzeg}o et al., 2019, Cell Reports 28, 65–77
July 2, 2019 ª 2019 The Authors.
https://doi.org/10.1016/j.celrep.2019.06.009Authors
E´va M. Szeg}o,
Antonio Dominguez-Meijide,
Ellen Gerhardt, ..., Johannes Attems,
Olaf Jahn, Tiago F. Outeiro
Correspondence
eva.szego@gmail.com (E´.M.S.),
touteiro@gwdg.de (T.F.O.)
In Brief
Szeg}o et al. identify HSP10 as a
modulator of alpha-synuclein-induced
mitochondrial impairment in striatal
synaptosomes. Age-associated increase
in the cytosolic and decrease in
mitochondrial levels of HSP10 results in a
reduction in the levels of SOD2 and of
synaptosomal ATP production on
demand. HSP10 overexpression delays
alpha-synuclein pathology both in vitro
and in vivo.
Cell Reports
ArticleCytosolic Trapping of a Mitochondrial
Heat Shock Protein Is an Early
Pathological Event in Synucleinopathies
E´va M. Szeg}o,1,9,* Antonio Dominguez-Meijide,1 Ellen Gerhardt,1 Annekatrin Ko¨nig,1 David J. Koss,2 Wen Li,7,8
Raquel Pinho,1 Christiane Fahlbusch,1 Mary Johnson,2 Patricia Santos,1 Anna Villar-Pique´,1 Tobias Thom,4 Silvio Rizzoli,3
Matthias Schmitz,4 Jiayi Li,7,8 Inga Zerr,4 Johannes Attems,2 Olaf Jahn,5 and Tiago F. Outeiro1,2,6,10,*
1Department of Experimental Neurodegeneration, Center for Nanoscale Microscopy and Molecular Physiology of the Brain,
University Medical Center, Waldweg 33, Go¨ttingen 37073, Germany
2Institute of Neuroscience, Medical School, Newcastle University, Framlington Place, Newcastle upon Tyne NE2 4HH, UK
3Department of Neuro- and Sensory Physiology, Center for Nanoscale Microscopy and Molecular Physiology of the Brain,
University Medical Center, Humboldtallee 23, Go¨ttingen 37073, Germany
4Department of Neurology, University Medical Center and German Center for Neurodegenerative Diseases (DZNE), Robert-Koch Street 40,
Go¨ttingen 37075, Germany
5Proteomics Group, Max Planck Institute of Experimental Medicine, Center for NanoscaleMicroscopy andMolecular Physiology of the Brain,
Hermann Rein Street 3, Go¨ttingen 37075, Germany
6Max Planck Institute of Experimental Medicine, Hermann Rein Street 3, Go¨ttingen 37075, Germany
7Institute of Heath Sciences, China Medical University, 110112 Shenyang, P. R. China
8Neural Plasticity and Repair Unit, Wallenberg Neuroscience Center, Department of Experimental Medical Science, BMC A10, 221 84 Lund,
Sweden
9Present address: Department of Biochemistry, Eo¨tvo¨s Lora´nd University, Pa´zma´ny P. stny 1/c, 1117 Budapest, Hungary
10Lead Contact
*Correspondence: eva.szego@gmail.com (E´.M.S.), touteiro@gwdg.de (T.F.O.)
https://doi.org/10.1016/j.celrep.2019.06.009SUMMARY
Alpha-synuclein (aSyn) accumulates in intracellular
inclusions in synucleinopathies, but the molecular
mechanisms leading to disease are unclear.We iden-
tify the 10 kDa heat shock protein (HSP10) as a medi-
ator of aSyn-induced mitochondrial impairments in
striatal synaptosomes. We find an age-associated
increase in the cytosolic levels of HSP10, and
a concomitant decrease in the mitochondrial
levels, in aSyn transgenic mice. The levels of super-
oxide dismutase 2, a client of the HSP10/HSP60
folding complex, and synaptosomal spare respira-
tory capacity are also reduced. Overexpression of
HSP10 ameliorates aSyn-associated mitochondrial
dysfunction and delays aSyn pathology in vitro and
in vivo. Altogether, our data indicate that increased
levels of aSyn induce mitochondrial deficits, at least
partially, by sequestering HSP10 in the cytosol and
preventing it from acting in mitochondria. Impor-
tantly, these alterations manifest first at presynaptic
terminals. Our study not only provides mechanistic
insight into synucleinopathies but opens new ave-
nues for targeting underlying cellular pathologies.
INTRODUCTION
A major pathological hallmark of Parkinson’s disease (PD) and
other synucleinopathies is the presence of intraneuronal inclu-This is an open access article under the CC BY-Nsions known as Lewy bodies (LBs) and Lewy neurites (LNs).
These inclusions are composed mainly of a-synuclein (aSyn)
but are known to also contain mitochondrial proteins (Leverenz
et al., 2007; Xia et al., 2008). Moreover, mitochondrial dysfunc-
tion has been implicated in the pathogenesis of PD: complex I
deficiency was detected in the substantia nigra (SN) (Schapira
et al., 1989), muscle (Blin et al., 1994), and platelets (Parker
et al., 1989) of PD patients, and mutations in several mitochon-
dria-related genes are associated with familial forms of the dis-
ease (Corti et al., 2011; Bose and Beal, 2016; Chang et al., 2017).
aSyn is considered primarily a cytoplasmic protein, but recent
evidence suggests that it may also accumulate in mitochondria
(Hu et al., 2019; Wang et al., 2019) and associate with mitochon-
dria-associated endoplasmic reticulum (ER) (Chinta et al., 2010;
Guardia-Laguarta et al., 2014). Whether aSyn plays a physiolog-
ical role in mitochondria is unclear, but increased aSyn levels
inhibit cellular respiration (Chinta et al., 2010; Wang et al.,
2019; Zambon et al., 2019), inducemitophagy andmitochondrial
fragmentation (Nakamura et al., 2008, 2011), affect mitochon-
drial Ca2+ homeostasis (Calı` et al., 2012) and protein import (Di
Maio et al., 2016) and turnover (Hu et al., 2019), and reduce
mitochondrial membrane potential (Banerjee et al., 2010), sug-
gesting a pathological role that culminates with mitochondrial
dysfunction.
Here, we hypothesized that aSyn-dependent mitochondrial
dysfunction might initiate in the synapse, because aSyn is likely
to start accumulating in the cytoplasm of the presynaptic termi-
nals (Kramer and Schulz-Schaeffer, 2007) and then progress
toward the perinuclear region to induce additional cellular pathol-
ogies. First, we screened for aSyn-interacting proteins in nerve
terminals (striatal synaptosomes) and identified the 10 kDa heatCell Reports 28, 65–77, July 2, 2019 ª 2019 The Authors. 65
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
shock protein (HSP10) as an aSyn interactor and mediator of
aSyn-associated mitochondrial dysfunction. Importantly, we ob-
tained detailed insight into the mechanisms through which the
accumulation of aSyn, a predominantly cytosolic protein, can
induce cellular pathologies by affecting mitochondrial functions.
We found that accumulation of aSyn inmiddle-age transgenic an-
imals sequesters HSP10 in the cytosol, reducing its mitochon-
drial function in the HSP10/HSP60 complex, which resulted in a
reduction in the levels of the client protein superoxide dismutase
2 (SOD2). This led to increased mitochondrial oxidative stress
and impaired respiration. Interestingly, improving mitochondrial
health by restoring the levels of HSP10 delayed aSyn-induced
mitochondrial pathology both in vitro and in vivo. Our findings
provide novel mechanistic information on the molecular under-
pinningsof PDandmight help indesigning novel therapeutic stra-
tegies for PD and other synucleinopathies.
RESULTS
The HSP10 Chaperonin Interacts with aSyn in Striatal
Synaptosomes
aSyn interacts with several synaptic and mitochondrial proteins
(Betzer et al., 2015) and affects both synaptic and mitochondrial
functions (Guardia-Laguarta et al., 2014; Calo et al., 2016; Di
Maio et al., 2016; Faustini et al., 2017; Hu et al., 2019; Wang
et al., 2019; Zambon et al., 2019). However, the effects of aSyn
in striatal synaptosomal mitochondria have not been addressed
in detail. To assess the molecular underpinnings of aSyn-medi-
ated toxicity in striatal mitochondria, we performed a prote-
omics-based unbiased screen for aSyn-interacting partners
in nerve terminals (synaptosomal component). We identified
aSyn-interacting proteins in preparations from transgenic over-
expressing human aSyn (wild-type aSyn [WTaSyn]) or from con-
trol mice. In total, we identified 67 proteins (Table S1). Of those
67 proteins, we selected the HSP10 for further validation,
because it forms, together with HSP60, a major folding complex
inmitochondria (David et al., 2013). HSP10 is amajor hub protein
for cellular interactions (Rizzolo et al., 2018) and regulates
several mitochondrial functions, including respiration, mem-
brane potential, and reactive oxygen species (ROS) removal.
Therefore, even subtle changes in its concentration may affect
the functionality of several proteins and cellular functions. The
regulation of HSP10 levels in neurological diseases is not well
understood (Hickey et al., 2000; Bross et al., 2007; Kim and
Lee, 2007; Bie et al., 2016; Bross and Fernandez-Guerra,
2016; Fan et al., 2017), and to our knowledge, this has not
been investigated in the context of synucleinopathies. To assess
whether the level of HSP10 is altered in human brain tissue, we
fractionated putamen samples of patients with PD and controls
(Figures 1A and 1B). We found that levels of synaptosomal
HSP10 were reduced in samples from patients. In contrast, the
levels of HSP60, the protein partner of HSP10 in the mitochon-
drial folding complex, and the levels of soluble aSyn were not
altered. In parallel, the levels of synaptosomal SOD2 were also
reduced in PD brains. Although we found no change in the levels
of soluble aSyn in striatal synaptosomes, we detected the coloc-
alization of HSP10 and phospho-aSyn (paSyn) in post-mortem
tissue (putamen) from PD patients and from patients with de-66 Cell Reports 28, 65–77, July 2, 2019mentia with LBs (DLBs) but not from control brains (Figure 1C;
Figure S1). We could also co-immunoprecipitate HSP10 and
aSyn from striatal synaptosomal samples of WT or aSyn trans-
genic mice (Figure 1D). In addition, we found colocalization of
HSP10 and aSyn in primary cortical neurons using a proximity
ligation assay (PLA; Figure S2). To further validate these results,
we used surface plasmon resonance (SPR), a technique that en-
ables estimation of the kinetics and binding constants for pro-
tein-protein interactions. We confirmed a high-affinity interaction
between HSP10 and monomeric, oligomeric, and pre-formed
fibrils (PFFs) of aSyn (Figure 1E). Interestingly, we found that
monomeric and PFFs of aSyn showed similar binding affinities
to HSP10 (monomeric: KD = 2.9 mM, ka = 11.92 M
1 s1, kd =
3.46 3 105 s1; PFF: KD = 5.27 mM, ka = 11.00 M
1 s1, kd =
5.95 3 105 s1) and that oligomeric aSyn had lower affinity to
HSP10 (KD = 27.2 mM, ka = 6.8 M
1 s1, kd = 1.85 3 10
4 s1).
The Subcellular Distribution of HSP10 Is Altered in
Middle-Age aSyn Transgenic Mice
Next, we assessed the levels of HSP10 in striatal synaptosomal
mitochondria of aSyn transgenic and control mice (Figure 2). The
levels of mitochondrial HSP10 were reduced in both young and
middle-age transgenic animals (Figures 2A–2D), but the levels
of total striatal HSP10 were not altered either by genotype or
by age (Figure 2F). In parallel, the levels of cytosolic HSP10
were increased in both young and middle-age A30PaSyn mice
(Figure 2E). To unequivocally confirm the identity and integrity
of HSP10, we used a parallel gel electrophoresis approach and
subjected the gel band corresponding to immunodetected
HSP10 to in-gel protein digestion followed by mass spectro-
metric protein identification (Ott et al., 2015). Both mitochondrial
and cytosolic HSP10 were identified with the same high
sequence coverage (Figures 2G and 2H).
Because the HSP60/HSP10 complex is an important player in
mitochondrial folding, we next asked whether there were func-
tional consequences of the age-associated decreased levels of
mitochondrial HSP10. To better distinguish between synaptic
and general effects, we fractionated striatal samples, prepared
from young or middle-age animals, into synaptosome and total
mitochondrial fractions (Figure S3A). We found reduced spare
respiratory capacity (SRC; a measure of mitochondrial function)
in synaptosomes prepared from young aSyn transgenic animals
(Figure S3B) but not in total mitochondria fractions (Figure S3C).
In middle-age transgenic mice, both synaptosomal (Figure S3D)
and total mitochondrial SRC (Figure S3E) decreased compared
with control animals. In addition, we found that mitochondrial
ROS handling (Figure S3F), mitochondrial membrane potential
(Figure S3G), and the opening of the mitochondrial permeability
transition pore (mPTP; Figure S3H) were also compromised
selectively in the striatal synaptic compartment but not in total
mitochondrial fractions (Figures S3I and S3J).
HSP10 Improves Mitochondrial Functions in Primary
Neuronal Cultures
Because we found reduced levels of mitochondrial HSP10 in the
brains of both PD patients and aSyn transgenic animals, we
hypothesized that this might be associated with the functional
deficits observed in mitochondria. Therefore, we next tested
Figure 1. aSyn Interacts with HSP10 in Striatal Synaptosomes and in Human Brain
(A) Synaptosome fractions from the putamen of patients with PD and age-matched controls (Ctrl) (n = 4 per group) were probed for the dopaminergic marker TH,
mitochondrial SOD2, synaptic marker synaptophysin (synapt.), aSyn, HSP10, and HSP60.
(B) Quantification of the HSP10/HSP60 and SOD2/HSP60 ratios in PD and control putamen.
(C) Representative confocal microscopy images of the putamen of a control and a PD patient show paSyn (red) staining and colocalization (orange) of paSyn and
HSP10 (green). Scale bar: 10 mm.
(D) Representative immunoblot of three independent experiments showing input samples and immunoprecipitation (pull-down) of aSyn (upper blots) or HSP10
(lower blots). Membranes were immunoblotted with anti-aSyn and anti-HSP10 antibodies. Mouse serum and immunobeads were used as negative controls
(serum Ctrl and Bead Ctrl, respectively).
(E) Surface plasmon resonance shows high-affinity binding of HSP10 to monomeric and PFF aSyn. aSyn was perfused for 1 min on sensor surfaces on which
HSP10 (10 and 20 mg/mL, upper and lower graphs, respectively) had been attached. The nonspecific binding was subtracted. Sensorgrams show the time course
of the HSP10-dependent SPR signal in resonance units (RU). Binding parameters are shown in the table below the graph.
Data are presented as mean ± SD. *p < 0.05. PD, Parkinson’s disease patient; mono, monomers; oligo, oligomers; PFFs, pre-formed fibrils.whether increasing the levels of HSP10 would ameliorate aSyn-
associated mitochondrial dysfunction. First, we generated an
in vitro model of synucleinopathies in primary striatal cultures,
in which moderate overexpression of aSyn resulted in mild mito-
chondrial dysfunction. Neurons were infected with lentivirus
encoding human WTaSyn, A30PaSyn, or GFP, as control pro-
tein. To test whether expression of HSP10 would modify
aSyn-induced mitochondrial dysfunction, neuronal cultures
were infected with lentivirus encoding for Flag-tagged
HSP10 (HSP10-Flag) or GFP. Therefore, we generated six
experimental groups: GFP+GFP, GFP+HSP10, WTaSyn+GFP,
WTaSyn+HSP-10, A30PaSyn+GFP, and A30PaSyn+HSP10.
We found that expression of human aSyn resulted in a 30%
increase in the total levels (both rodent and human) of aSyncompared with control cells (GFP+GFP versus WTaSyn+GFP
or A30PaSyn+GFP) (Figures 3A and 3B; Figure S4A). Expression
of human aSyn reduced the levels of endogenous HSP10 just
moderately (Figure S4B) but did not affect the levels of HSP60
(Figure 3B; Figure S4C). Expression of human aSyn increased
ER stress (elevated levels of growth arrest and DNA damage
153 [GADD153]) (Figures S4D and S4E) and reduced the levels
of the mitochondrial serine protease high temperature-regulated
A2 (HtrA2) (Figure S4F) and SOD2 (Figures 3B and 3C). mPTPs
were more open in cells expressing A30PaSyn (Figure S4G).
Interestingly, although basal mitochondrial ROS levels were
not increased (Figure S4H), removal of mitochondrial ROS was
less efficient in H2O2-treated cells (Figure 3D) when human
aSyn was expressed. In contrast, basal cytoplasmic ROS levelsCell Reports 28, 65–77, July 2, 2019 67
Figure 2. HSP10 Re-localizes from the Mitochondria into the Cytosol of Middle-Age aSyn Transgenic Mice
(A) Representative immunoblot image showing the levels of the mitochondrial marker HSP60 (red) and the cytoplasmic markers TH (green) and GAPDH in the
mitochondrial or cytoplasmic fractions prepared from striatal samples.
(B) Immunoblot images show mitochondrial (left) and cytoplasmic (right) HSP10 levels in young and old, control (WT), and WTaSyn transgenic mice.
(C) Immunoblot images show mitochondrial (left) and cytoplasmic (right) HSP10 levels in young and old, control (WT), and A30PaSyn transgenic mice. Mito-
chondrial levels of HSP10 decreased in both young andmiddle-ageWTaSyn (upper left) and A30PySyn (lower left) mice. In contrast, cytoplasmic levels of HSP10
increased with age in transgenic mice (in WTaSyn mice, it was detectable just in middle-age animals; upper right panel). In A30PaSyn mice, the levels of
cytoplasmic HSP10 were increased already in younger animals (lower right) and were further increased with age.
(D) Quantification of the mitochondrial HSP10 levels of WTaSyn and control (upper panel) and A30PaSyn and its control (lower panel) shows reduced protein
signal in both young and old transgenic animals.
(E) Quantification of cytoplasmic HSP10 signal shows increased level of HSP10 in agedWTaSynmice, and in both young and old A30PaSynmice, comparedwith
control.
(F) Representative immunoblots showing the total level of HSP10 in WT and aSyn transgenic mice. No differences in the total levels of HSP10 were found.
(G) Colloidal Coomassie staining (upper image), HSP10 immunoblot (middle image), and pseudo-colored overlay (lower image) of the same protein lysates. The
overlay was used to determine the region to be excised from the Coomassie gel for subsequent MS protein identification (areas indicated by rectangles). Mito,
mitochondria sample; Cyto, cytoplasmic sample; conc Cyto, concentrated cytoplasmic sample.
(H) In the amino acid sequence of HSP10 (UniProtKB/Swiss-Prot Q64433), peptides identified by MS are underlined (orange, peptides identified from the
mitochondrial fraction; dark green, peptides identified from the cytoplasmic fraction, major lower band; light green, peptides identified from the cytoplasmic
fraction, minor upper band).
Data are presented as mean ± SD. *p < 0.05.were higher (Figure S4I), but H2O2-induced ROS elimination was
identical in GFP-expressing and in human aSyn-expressing
cells (Figure S4J). Expression of both WTaSyn and A30PaSyn
significantly reduced the SRC of striatal neurons, with a
greater decrease in the A30PaSyn-expressing cultures (Figures
3E and 3F).
Expression of HSP10-Flag resulted in a2-fold increase in the
total levels of HSP10 protein (GFP+HSP10, WTaSyn+HSP10,
and A30PaSyn+HSP10; Figure 3B; Figure S4B). In WTaSyn-
expressing cells, overexpression of HSP10 resulted in increased68 Cell Reports 28, 65–77, July 2, 2019SOD2 levels (Figures 3B and 3C), and consequently,
removal of mitochondrial ROS upon H2O2 treatment was
improved (Figure 3D). In addition, the mitochondrial HtrA2 levels
(Figures S4D and S4F) and SRC (Figures 3E and 3F) were
both normalized. In contrast, although basal cytoplasmic
ROS decreased in cells co-expressing WTaSyn and HSP10
(Figure S4I), ER stress levels were not changed (Figures S4D
and S4E).
Overexpression of HSP10 in A30PaSyn-infected cells
improved the elimination of mitochondrial ROS after oxidative
Figure 3. Hsp10 Mitigates Mitochondrial Dysfunction in Primary Neurons Expressing Human WTaSyn
(A) Immunofluorescence images of primary neurons stained for HSP10-Flag (green) and HSP10 (red) showing colocalization (yellow). HSP10-Flag is not ex-
pressed in glial cells (arrows). Scale bar: 20 mm.
(B) Representative immunoblots of three independent experiments showing the levels of HSP10, HSP10-Flag, GFP, and endogenous and human aSyn (human
aSyn with T2A tag [molecular weight (MW) 1.3 kDa higher than that of endogenous rat aSyn; Tang et al., 2009) in primary neurons. The levels of endogenous
aSyn and HSP60 are not changed, while the levels of SOD2 decreases with human aSyn expression (n = 3). Quantifications of aSyn, HSP10, and HSP60 are
shown in Figures S5A–S5D).
(C) Quantification of SOD2 protein levels in primary cultures. Levels of SOD2 decrease in cells expressing WT or A30P aSyn, and increased HSP10 expression
improves only WTaSyn-induced SOD2 protein loss.
(D) Expression of human WTaSyn or A30PaSyn reduced mitochondrial ROS handling, while expression of HSP10 improved ROS handling in cells expressing
human aSyn and in control cells expressing GFP, but not in cells expressing A30PaSyn (n = 3).
(E and F) Primary neuronal cultures expressing human aSyn displayed reduced SRC (n = 8). HSP10 improved SRC in cells expressing WTaSyn but not in cells
expressing A30PaSyn.
(E) Graph displaying the changes in the SRC in response to various treatments, normalized to control cultures.
(F) Mitochondrial respiration of the various cultures measured by OCR levels under basal conditions (measurement at 5 and 10 min) or following the addition of
oligomycin, the uncoupler FCCP, or rotenone and antimycin. SRC was quantified by normalization of OCR levels to the total numbers of cells.
Data are presented as mean ± SD. *p < 0.05.
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Figure 4. HSP10 Delays aSyn Pathology in Primary Neuronal Cultures
(A) Microscopy images (representative of three independent experiments) showing the localization of paSyn (green) in primary neurons overexpressing human
WTaSyn 2 or 4 weeks after viral vector transduction. Scale bar: 20 mm.
(B) Localization of paSyn-positive signal was quantified in cultures after 2, 3, or 4 weeks of aSyn expression. paSyn signal was classified as neuritic (neurite), when
signal was present just in the neurites of a single neuron; juxtacellular (soma), when signal was present just in the perinuclear area; ormixed (neurite + soma), when
both neuritic and juxtacellular signal was observed.
(C–E) aSyn solubility in Triton X-100 increased in cultures infected with HSP10.
(C) Representative immunoblot shows aSyn in the Triton X-100 (TX) insoluble fraction.
(D) The levels of aSyn did not change in the Triton X-100 soluble fraction (lysates from the same preparation, as in (C).
(E) Ratio of Triton X-100 insoluble and soluble aSyn decreases in ‘‘old’’ cultures when HSP10 is expressed (n = 3).
(F) Microscopy images (representative images of three independent experiments) showing the colocalization of paSyn (green) and synapsin (red) in primary
neuronal cultures expressing WTaSyn and HSP10 or GFP, as a control, 2, 3, or 4 weeks of aSyn expression. Scale bar: 20 mm.
(G) Colocalization was assessed by Mander’s overlap coefficient using ImageJ JACoP plugin after 2 or 4 weeks of aSyn expression. Almost complete coloc-
alization was observed in young cultures (Mander’s coefficient0.95), indicating the presynaptic presence of paSyn. In old cultures, colocalization of paSyn and
synapsin was lower (Mander’s coefficient0.46 ± 0.04 for WTaSyn and 0.32 ± 0.06 for A30PaSyn) but remained higher in cultures expressing HSP10 (0.64 ± 0.05
for WTaSyn and 0.46 ± 0.07 for A30PaSyn).
Data are presented as mean ± SD. *p < 0.05.stress (Figure 3D) but did not alter the levels of SOD2 or HtrA2.
Similarly, SRC was not improved upon HSP10 overexpression
(Figures 3E and 3F).
HSP10 Reduces aSyn Pathology
The aggregation of aSyn is enhanced in oxidative environments
(Hashimoto et al., 1999; Fernandes et al., 2014; Scudamore
and Ciossek, 2018). Because increasing the levels of HSP1070 Cell Reports 28, 65–77, July 2, 2019improved mitochondrial ROS handling and decreased basal
cytoplasmic ROS levels, we next tested whether HSP10 overex-
pression modulated aSyn aggregation. We compared the levels
of aSyn phosphorylation on S129 (paSyn, used as a readout of
aSyn pathology) in neurons expressing WTaSyn or A30PaSyn
together with either HSP10 or GFP (see the six groups above)
(Oueslati, 2016). After 2 weeks in culture, paSyn was found
mostly in puncta along the neurites (Figures 4A and 4B) and
Figure 5. HSP10 Reduces aSyn Aggregation In Vitro
(A) Representative SDS-PAGE image of the recombinant proteins used for further experiments. Protein identity was confirmed by mass spectrometry analyses.
Left blot: 0.1 mg HSP10 and 0.1 mg monomeric aSyn were loaded on the gel. Right blot: 0.05 mg monomeric and 0.1 mg oligomeric or PFF aSyn were loaded on a
native gel.
(B) Quantification of the results of the RT-QuiC experiment shows that HSP10 (1/10 of the amount of aSyn) increases the aggregation of WTaSyn from the
monomers, while A30PaSyn aggregation was not affected by HSP10.
(C) When aSyn PFF seeds are present, HSP10 reduces WTaSyn aggregation. Left panels in (B) and (C): quantification of the relative ThioT fluorescence signal
after the last cycle of the RT-QuIC assay. Right panels in (B) and (C): representative curves showing the fluorescent signal over time.
(D) Folding activity of the HSP60/HSP10 complex after pre-incubation of HSP10 with 100 nMmonomeric, oligomeric, or PFFs of aSyn (‘‘pre-incubation’’) or after
incubation of different aSyn species together with HSP10 and HSP60 (‘‘incubation’’). FC, folding control; the complex was incubated with BSA instead of
aSyn; Ctrl, folding activity without addition of ATP; +Ctrl, activity in the presence of the folding client without heat shock.
Data are presented as mean ± SD. *p < 0.05.colocalized almost completely with synapsin (Figures 4F and 4G)
in all cultures expressing human aSyn. Two weeks later, most
neurons expressing human aSyn + GFP displayed paSyn in the
soma, and the colocalization of paSyn and synapsin was
reduced. Interestingly, HSP10 delayed the re-localization of pa-
Syn-positive puncta from the neurites toward the soma, and the
colocalization with synapsin remained relatively high even after
4 weeks in culture (Figures 4B and 4G).
To further confirm the modulation of aSyn aggregation by
HSP10, we assessed the solubility of aSyn in Triton X-100 in
the older cultures (Figures 3C–3E). We found that the ratio
of insoluble to soluble aSyn decreased in primary cells
expressing WTaSyn+HSP10 compared with cells expressing
WTaSyn+GFP. However, HSP10 expression had no effect in
A30PaSyn-expressing cells (Figures 4C–4E).
Next, we assessed the conversion of monomeric aSyn
into fibrils in vitro, using the real-time quaking-induced con-
version (RT-QuIC) assay (Candelise et al., 2019; van Rumund
et al., 2019). Briefly, WTaSyn or A30PaSyn monomers were
incubated in the presence or absence of HSP10, and the
aggregation was monitored by measuring thioflavin T fluores-
cence. Alternatively, WTaSyn or A30PaSyn monomers
were seeded with PFFs of WTaSyn in the presence of
HSP10. Only freshly thawed aSyn monomers were used,
and the quality of the preparations was assessed using
immunoblot (Figure 5A). WTaSyn monomers aggregated
even without PFF seeding (Figure 5B) and HSP10 increased
aggregation. Interestingly, in the presence of PFF seeds,
HSP10 decreased aSyn aggregation (Figure 5C). In contrast,
A30PaSyn monomers formed almost no thioflavin T-positive
species without PFF seeding, irrespective of the presence of
HSP10 (Figure 5B). Although the presence of PFF seeds
increased A30PaSyn aggregation, HSP10 had no effect
(Figure 5C).aSyn Affects HSP10/HSP60 Folding Activity
Because we found increased levels of cytoplasmic HSP10 in
middle-age transgenic mice, we hypothesized that cytosolic
aSyn might bind to and, therefore, sequester HSP10 in the cyto-
plasm, reducing the amount of protein that would normally
localize in mitochondria. As a corollary of this hypothesis, this
should result in reduced folding capacity of the HSP60/HSP10
complex. To test this, we used two distinct approaches. One
mimicked a situation in which different aSyn species (monomers,
oligomers, and PFFs) would interact with Hsp10 in the cytosol
(Figure 5D, pre-incubation with HSP10). The other mimicked a
situation in which the different aSyn species would interact
with the HSP60/HSP10 complex in mitochondria (Figure 5D, in-
cubation with HSP10 and HSP60). Interestingly, while aSyn
monomers increased the folding activity when pre-incubated
with HSP10 (before adding HSP60), incubation of aSyn together
with HSP10 and HSP60 did not change complex activity. Oligo-
meric aSyn species reduced the folding activity only when added
together with HSP10 and HSP60. In contrast, aSyn PFFs pre-
incubated with HSP10 significantly reduced the folding activity
of the complex but had no effect when incubated together with
HSP10 and HSP60 (Figure 5D). These findings suggest confor-
mation-specific interactions between aSyn and HSP10, consis-
tent with the SPR data, and suggest that aggregated aSyn in
the cytosol impairs the activity of the HSP10/HSP60 complex.
HSP10 Improves Mitochondrial Function In Vivo
Next, to determine whether we could rescue aSyn-associated
pathologies in vivo, we injected lentiviruses encoding either
HSP10 or GFP in the SN of WT or aSyn transgenic mice.
HSP10 and GFP were detected both in synaptosomes prepared
from the striatum and in dopaminergic neurons of the SN (Fig-
ures 6A and 6D). One month after viral injection, neither the
number of tyrosine hydroxylase (TH)-positive (dopaminergic)Cell Reports 28, 65–77, July 2, 2019 71
Figure 6. Viral Vector-Mediated Overexpression of HSP10 in the Substantia Nigra Restores aSyn-Induced Mitochondrial Dysfunction and
Reduces ER Stress in Striatal Synaptosomes
(A) Representative immunoblot showing the levels of human aSyn, HSP10-Flag, and GFP in striatal synaptosomes of WT control or transgenic mice infected with
HSP10-Flag or GFP encoding viruses in the SN.
(B and C) Representative immunoblots showing the striatal levels of the post-synaptic density protein PSD95, presynaptic synaptophysin, SOD1, SOD2,
GADD153, and paSyn in the Triton X-100 soluble fraction (B), or the striatal levels of paSyn in the Triton X-100 insoluble fraction, and quantification of ratio of
soluble to insoluble aSyn (C) after the intranigral injection of lentiviruses encoding GFP or HSP10-Flag. Symbols are in (E)–(H). Quantification of the relative levels
of GADD153, SOD1, and SOD2 is shown in Figures S5C–S5E (n = 3).
(legend continued on next page)
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neurons nor the total number of neurons (Nissl) changed
compared with control mice (Figures S5A and S5B). We found
no alterations in the levels of synaptophysin or PSD95 in striatal
synaptosomes (Figure 6B). ER stress (GADD153) was increased,
and SOD1 and SOD2 levels were decreased in transgenic mice
(Figure 6C). Expression of HSP10 did not change the levels of
SOD1. In contrast, it decreased the levels of GADD153 in
WTaSyn transgenic animals (Figure 6B). The levels of synapto-
somal SOD2, a protein folded by the HSP60/HSP10 complex,
was restored to control levels upon overexpression of HSP10
(Figure 6B). Interestingly, increased striatal HSP10 also reduced
aSyn aggregation in synaptosomes of WTaSyn transgenic mice,
as assessed using Triton X-100 solubility (Figure 6C).
Next, we hypothesized that the restoration of SOD2 levels in
HSP10-injected animals might reduce mitochondrial ROS levels
and/or improve ROS handling. Although basal mitochondrial
ROS levels were not altered by HSP10 overexpression, the
handling of ROS upon H2O2 stress improved in HSP10-injected
WTaSyn transgenic mice and was identical to that observed in
control animals (Figures 6E and S5F–S5H).
Because the folding and import of several mitochondrial pro-
teins, including components of the respiratory chain, are medi-
ated by the HSP60/HSP10 complex (Tang et al., 2016), we
next tested whether HSP10 would also restore mitochondrial
SRC. We found that HSP10 significantly increased SRC in stria-
tal synaptosomes prepared from WTaSyn animals but not from
A30PaSyn mice (Figures 6G and 6H).
DISCUSSION
Consistent with the occurrence of functional synaptic alterations
in early, preclinical stages of synucleinopathies, we discovered
that in the nigrostriatal system, aSyn-induced synaptic mito-
chondrial pathology starts prior to the total mitochondrial pathol-
ogy. We report that aSyn interacts with HSP10 in the striatal
synaptic compartment and that this interaction results in the
sequestration of HSP10 in the cytosol in conditions of increased
aSyn load, leading to the impairment of several mitochondrial
functions. We hypothesized that this happens because when
HSP10 is sequestered in the cytosol, the normal folding of client
proteins of the mitochondrial HSP10/HSP60 complex is
compromised. By increasing the levels of HSP10, we improved
aSyn-associated mitochondrial dysfunction and delayed aSyn
pathology.
When levels of aSyn are increased, because of age-associ-
ated changes in its turnover or because of the effect of PTMs
(de Oliveira et al., 2017; Vicente Miranda et al., 2017), aSyn
may gain toxic properties and associate with mitochondria.(D) Representative microscopy images of the SN of wild-type (WT BDF orWT Bl6)
HSP10-Flag encoding virus. Scale bar: 200 mm (103) or 20 mm (603). Thirty micr
was stained with anti-tyrosine hydroxylase antibody (TH; red) to detect dopamine
exogenous protein, and DAPI (blue).
(E) Mitochondrial ROS handling in striatal synaptosomes improved in WTaSyn m
(F) The FCCP-induced depolarization in striatal synaptosomes of WTaSyn mice,
(G) Change in SRC in striatal synaptosomes normalized to preparations from WT
(H) Mitochondrial respiration measured by relative OCR levels in striatal synaptos
addition of oligomycin (15 min), the uncoupler FCCP (20 min), or rotenone and a
Data are presented as mean ± SD. *p < 0.05.Consistently, overexpression of aSyn or treatment of cells with
aSyn oligomers or fibrils also induces severe mitochondrial def-
icits, including fragmentation (Nakamura et al., 2011), mitophagy
(Chinta et al., 2010), and impaired mitochondrial protein import
(Di Maio et al., 2016). However, the precise effect of aSyn on
mitochondrial function is still controversial. Although some
studies show no effect of aSyn in dopaminergic nerve terminals
(Pathak et al., 2017), others have reported protection even
against the mitochondrial toxin MPP+ (Dauer et al., 2002; Foun-
taine and Wade-Martins, 2007).
To gain insight into the initial effects of aSyn in nerve terminals,
we searched for aSyn interactors in striatal synaptosomes.
Among several other candidates, we identified HSP10 as a novel
aSyn-interacting protein and asked whether manipulating the
levels of this small heat shock protein could reverse aSyn-asso-
ciated cellular pathologies. HSP10 is encoded by a nuclear gene
(HSPE1, 2q33.1), arranged head to head with the gene encoding
HSP60 and controlled by the same bi-directional promoter (Han-
sen et al., 2003). In mitochondria, HSP10 assembles into either
an asymmetric (one HSP10 heptameric ring) or a symmetric
(two rings) complex with an HSP60 14-mer. Interestingly, the
levels of HSP10 limit the formation of the symmetric complexes,
and the asymmetric complex has reduced folding capacity (Ni-
semblat et al., 2015). Because the HSP10/HSP60 complex is
one of themost important players inmitochondrial quality control
(Horwich et al., 2007; Campos et al., 2016), reduced function of
the complex results in embryonic lethality (Christensen et al.,
2010), and a heterozygous mutation in the HSPE1 gene associ-
ates with severe, early-onset neurological disorder in humans
(Bie et al., 2016). Although the mutant protein is functional, its
resistance to proteases is substantially reduced, resulting in an
almost 2-fold reduction in the HSP10/HSP60 ratio. Because
decreased HSP10 concentration forces the formation of the
asymmetric, less efficient, folding complex, the levels of client
proteins, such as SOD2, are reduced to just 20% of the normal
levels, and mitochondrial ROS levels are increased (Azem
et al., 1995). Our finding that, in parallel with reduced mitochon-
drial HSP10 levels in striatal synaptosomes, both mitochondrial
ROS removal and SOD2 level are decreased, suggests that
HSP10 may play a central role in aSyn-associated mitochondrial
dysfunction in synucleinopathies. Although in our model, the
levels of other mitochondrial proteins (e.g., TOM20, HSP60, fra-
taxin; data not shown) were not altered, we cannot rule out that
aSyn alters mitochondrial protein import through another mech-
anism. Our results also suggest that the A30P mutation in aSyn
may potentiate the interaction between aSyn and HSP10, lead-
ing to an earlier decrease in mitochondrial HSP10 levels and
mitochondrial dysfunction.and transgenic (WTaSyn or A30PaSyn) mice after injection of GFP as control or
ometer coronal section containing the SN where the virus injection was visible
rgic neurons, anti-GFP or anti-Flag antibody (green) to detect the expression of
ice upon HSP10 overexpression (n = 4).
but not in A30PaSyn mice, was reduced upon HSP10 overexpression (n = 4).
control animals (n = 5).
omes, under basal conditions (measurement at 5 and 10 min) or following the
ntimycin (25 min).
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Given that HSP10 is synthetized in the cytosol, and that aSyn
is also primarily a cytosolic protein, we hypothesized that the
main site for the interaction between the two proteins would be
the cytosol. We predicted that increased levels of aSyn would
bind more HSP10 and, consequently, reduce its mitochondrial
levels and activity, thereby leading to the impairment of mito-
chondrial quality control and respiration at synapses. We also
hypothesized that as a chaperone, HSP10 might affect aSyn ag-
gregation. We tested both hypotheses and assessed (1) HSP60/
HSP10 folding activity in the presence of different aSyn species
and (2) the aggregation of aSyn in the presence of HSP10. We
found that aggregated forms of aSyn (PFFs) did not change the
folding activity of the already formed HSP10/HSP60 complex
per se. However, pre-incubation of PFFs with HSP10, to mimic
the interaction between aSyn and HSP10 in the cytosol, reduced
the folding activity of the complex by approximately 50%.
Because under pathological conditions aSyn accumulates and
aggregates in the cytosol, where newly synthetized, non-com-
plexed HSP10 is also present, our data suggest that certain
aggregated forms of aSyn interact with HSP10 in the cytosol,
prevent its import into mitochondria, and thereby reduce the ac-
tivity of the HSP60/HSP10 complex. This is supported by the
SPR data showing that aSyn monomers and PFFs interact with
HSP10 with high affinity. In comparison, the dissociation con-
stants obtained in the SPR experiment were identical to those
described for aSyn and S100A9 interaction (Horvath et al.,
2018). In addition, we found a significant fraction of HSP10 in
the cytoplasm, alongside decreased levels of mitochondrial
HSP10.
We also found that HSP10 influenced the aggregation of aSyn.
Although monomeric aSyn aggregated faster in the presence of
HSP10, the aggregation was slower when both aSyn PFF and
HSP10 were present. These results suggest that aSyn aggrega-
tion may start at lower concentrations when HSP10 is present
and that once aSyn seeds are formed, the aggregation process
is slowed down by HSP10. The aggregation properties of A30P
aSyn species were not altered by HSP10. Because the effects
of A30P aSyn on mitochondria appeared to be stronger than
those observed with WT aSyn, and increasing the levels of
HSP10 did not improve aSyn pathology or mitochondrial
dysfunction, one might speculate that A30P aSyn oligomeric or
monomeric species trap HSP10 and induce pathology. Further
investigations in future will be necessary to clarify the signifi-
cance of these findings.
The connection between aSyn pathology and mitochondrial
dysfunction in PD is complex. Dysfunctional mitochondria pro-
duce less ATP and more ROS, and because of the high energy
demand in the synaptic compartment, lowering ATP leads to
synaptic dysfunction (Rangaraju et al. 2014) and triggers aSyn
accumulation (Nakata et al., 2012). In addition, mitochondrial
health correlates with axonal transport, regeneration (Smith
and Gallo, 2018), and, consequently, the clearance of aSyn
(Oh et al., 2017). Similarly, increased ROS levels facilitate aSyn
aggregation (Tabner et al., 2006; Fernandes et al., 2014). This
suggests that improving mitochondrial health might also
contribute to a reduction in the levels of pathological species
of aSyn. Other chaperones, such as HSP27 (Outeiro et al.,
2006; Cox et al., 2018), HSP70 (Outeiro et al., 2008; Gao et al.,74 Cell Reports 28, 65–77, July 2, 20192015; Aprile et al., 2017), and HSP90 (Du et al., 2014; Xiong
et al., 2015), have already been shown to modulate aSyn
aggregation and toxicity. However, in our model, we found no
evidence for aSyn-associated changes in the levels of these
chaperones. We found that the levels of HSP10 were reduced
upon aSyn overexpression and that overexpressing HSP10 miti-
gated most mitotoxic effects of WT aSyn but not of A30P aSyn.
Importantly, expression of HSP10 in the SN ofWT aSynmice, but
not A30P aSyn mice, improved mitochondrial respiration and
ROS handling in striatal synapses, consistent with the effects
observed in synaptic terminals.
In general, we found that A30P aSyn induced stronger cellular
pathologies compared with WTaSyn. Our data suggest that the
differences between WT and A30P aSyn might be because of
the mutation, rather than a simple protein load effect, because
in our cell culture model the levels of human aSyn were identical
(Figure 2B). The levels were also similar in the two transgenic
mouse lines used (Figure 4A). A30P mutant aSyn impairs auto-
phagy (Song et al., 2009), which leads to higher ER stress and,
ultimately, mitochondrial dysfunction (Ganguly et al., 2018), sug-
gesting also a more downstream, non-HSP10-dependent effect.
Consistently, we found that overexpression of HSP10 was less
efficient in mitigating those pathologies. The molecular effects
of the A30P mutation on aSyn function and toxicity are still un-
clear. Although a recent study suggests that the A30P mutation
induces a loss of function (Pozo Devoto et al., 2017), others sup-
port an age-dependent reduction inmitochondrial function (Rob-
son et al., 2018) and increased toxicity (Ysselstein et al., 2017).
We have also recently reported different effects on gene expres-
sion in both cell and animal models (Paiva et al., 2018; Pinho
et al., 2019), and different aggregation propensity (La´zaro
et al., 2014), suggesting that multiple effects may contribute to
the differences observed.
In conclusion, our study provides novel insight into the molec-
ular mechanisms underlying aSyn-mediated mitochondrial
dysfunction in PD and other synucleinopathies and opens novel
perspectives for the design of strategies aimed at improving
cellular pathologies associated with these devastating diseases.STAR+METHODS
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Ethical statement and animal lines
Animal procedures were performed in accordance with the European Community (Directive 2010/63/EU), institutional and national
guidelines (Landesamt f€ur Verbraucherschutz, Braunschweig, Lower Saxony, Germany, license number: 33.9-42502-04-17/2413).
All mice were housed at controlled temperature and 12:12 h light/dark cycle. Number of animals included in the analysis was esti-
mated by power analysis (R software packages, Vienna, Austria), and selection of animals was randomized. Mice that lost more
than 20% of the body weight during the treatment were excluded from the experiment. Young (2-3 months old) and middle-age
(5-7months old) wild-type (DBA/2F1 (DBA; control ofWTaSyn) or C567BL/6J (Bl6; control of A30PaSyn) and human aSyn-expressing
mice (Thy-1 promoter; WT or A30P human aSyn (Kahle et al., 2000; Rockenstein et al., 2002; Szeg}o et al., 2012)) were used in the
study. Only male mice, or female and male mice mixed groups (only for lentivirus injection) were used.
Patients and controls
Human brain samples frompatients with PD or DLB, and control individuals were obtained from the Newcastle Brain Tissue Resource
(NBTR) or from the Regional Ethical Review Board of Lund University, Sweden (2014/631). Samples were classified according to the
disease diagnostics and were anonymized, information about age, sex and post-mortal delay are indicated in Table S2. The use of
humanmaterial was approved by the Ethics Committee for Using Human Brain Samples for Fundamental Research, University Med-
ical Center, Go¨ttingen.
METHOD DETAILS
Lentivirus injections and tissue dissection
To inject lentivirus, only young (2-4months old) female andmalemice were used. Two times 0.5 ml lentivirus (adjusted to 1x107 TU/ml)
were injected in the substantia nigra of both hemispheres (de Oliveira et al., 2017). One month after the injection, brain tissue was
rapidly dissected for mitochondrial assays and protein analysis and processed immediately. For immunofluorescence analysis,
brains were fixed in 4% PFA, and after cryoprotection (30% sucrose), 30 mm coronal sections were cut.
Primary neuronal culture
Primary neuronal cultures (prepared from E18 Wistar rat embryos, mixed sex) were infected with lentivirus coding GFP, WTaSyn or
A30PaSyn on day 4 (MOI 1), and with GFP or HSP10-Flag on day 7 (MOI 1). Cells were maintained in Neurobasal supplemented with
B27 and 2mM glutamax (Villar-Pique´ et al., 2016; Szeg}o et al., 2017).
Constructs
Full-length human aSyn cDNA (SNCA, gene association NM000345- WT and A30P mutation) was sub cloned into a 3rd-generation
lentiviral vector CD526A-1, followed by a T2A-GFP sequence, under the original vector promoter (EF1a). The inserts (aSyn, WT and
A30P mutation) including the Kozak sequence have been generated by PCR. The CD526A-1 vector containing only the T2A-GFP
cassette was used for control experiments. The T2A sequence is cleaved after translation, generating two proteins from a single
open reading frame and resulting in stoichiometric expression of the gene of interest and the fluorescent reporter (Tang et al., 2009).
Full-length human heat shock protein family E (HSP10) member 1 (HSPE1, gene association NM 0022157.2) was sub cloned into a
3rd-generation lentiviral plasmid with hUbC-driven EGFP, where the original GFP cassette has been replaced by the HSPE1 gene
including the Kozak sequence and a C-terminal Flag tag. The FUGW vector containing only the GFP cassette was used for control
experiments.e3 Cell Reports 28, 65–77.e1–e6, July 2, 2019
Cell lysis, tissue fractionation, western blotting and immunoprecipitation
For protein quantification and detection of Triton X-100 insoluble proteins, cells were lysed in 1% Triton X-100. After centrifugation
(14 000 g, 30 min), supernatant was used as Triton X-100 soluble, the pellet as Triton X-100 insoluble fraction. For immunoblotting,
tissue samples or cells were collected and homogenized in RIPA buffer (50 mM Tris, pH 8.0, 0.15 M NaCl, 0.1% SDS, 1.0% NP-40,
0.5% Na-Deoxycholate, 2 mM EDTA, supplemented with Complete Protease Inhibitor Cocktail (Roche, Mannheim, Germany)), for
co-immunoprecipitation (co-IP) assay, in IP buffer (50mMTris-HCl pH 7.5; 0.5mMEDTA; 150mMNaCl; 0.05%NP40) supplemented
with inhibitor cocktail. In each IP sample, 150 mg of total protein lysate was pre-cleared (20 ml of protein G beads (Invitrogen, Barce-
lona, Spain) for 30 min at 4C; the beads were later treated as the lysates and used as IgG controls) and then incubated with 2 mg of
one the IP antibodies (aSyn (BD) or HSP-10 (Santa Cruz)) overnight at 4C. Then samples were mixed with 15 ml protein G beads and
incubated for 3 h. Beads were washed 6 times with IP buffer, and proteins were eluted by using 3x 150 ml acidic buffer (0.2 M glycine
pH 2.4). Eluates were then precipitated with trichloric acid, resuspended in 50 ml protein sample buffer (125 mM Tris-HCl, 4% SDS
0,5% Bromophenol blue, 4 mM EDTA, 20% Glycerol, 10% b-mercapto-ethanol, pH 6.8) and boiled. Proteins from 10 mg lysate as
input or from 10 ml of the supernatants of IP were separated via SDS-PAGE gel and then transferred onto nitrocellulose membrane.
After blocking, membranes were first incubated in the presence of one of the primary antibodies (aSyn, HSP10, Flag, GADD153,
HtrA2, HSP60, paSyn, hmaSyn, SOD2, synaptophysin, PSD95, TH, actin, GAPDH) and then with IRDye 800CW or 680LT (Li-Cor,
Bad Homburg, Germany), respectively. Membranes were imaged using Li-Cor Odyssey CLx imaging system. Intensities of specific
bands were normalized. Synaptosomes, total mitochondria and cytosolic fractions were prepared from the same brain as described
below (Dunkley et al., 2008), from young and middle-age mice. Briefly, striatal samples were homogenized in isotonic sucrose solu-
tion (320 mM sucrose, 1 mM EDTA, 5 mM TRIS, 250 mMDTT, pH 7,4), nuclei and non-lysed tissue was pelleted (1000 g, 5 min), then
supernatant was separated on Percoll gradient. (31 000 g, 4C, 20min). Synaptosomal fraction was collected from the band between
buffer containing 23% and 15% Percoll, respectively. Mitochondria fractions were collected after centrifugation of the nuclei-
pelleted lysate at 6000 g. Collected fractions were washed in assay buffer (synaptosome: 3.5mM KCl, 120mM NaCl,
1.3mM CaCl2, 0.4 mM KH2PO4, 1.2 mM Na2SO4, 15 mM D-glucose, 10 mM pyruvate, 0.4% (w/v) fatty acid-free bovine serum albu-
min, 10 mM TES (N- [tris(hydroxymethyl)methyl]-2-aminoethanesulfonic acid), pH 7.4.; mitochondria: 70 mM sucrose, 210 mM
mannitol, 5.0 mM HEPES, 1.0 mM EGTA, 0.5% (w/v) fatty acid free BSA, pH 7.2). 10 mg (Seahorse) or 50 mg (other mitochondrial as-
says) protein was used for biochemical assays (protein concentrations were determined by the Bradford assay (Bio-Rad)).
Mitochondrial assays
XF96 analyzer was used to measure respiration according to the manufacturer‘s instructions. Briefly, assay plates were
coated before use with 0.0033% (v/v) polyethyleneimine solution (100ml/well) overnight at room temperature. Synaptosomes or
mitochondria were attached by centrifugation (4000 g, 20 min, 4C) to coated Seahorse plates (10 mg protein/well) or 96-well micro-
plates (50 mg/well). This was followed by dye loading for biochemical assays, or direct measurement in the XF96 analyzer. Spare res-
piratory capacity (SRC) was calculated as the difference between the maximal (FCCP) and basal respiration. % change in SRC is the
relative change compared to control SRC. Tetraethylbenzimidazolylcarbocyanine iodide (JC-1, 50 nM, 30 min loading at 37C)) was
used to measure mitochondrial membrane potential, according to manufacturer’s instructions. Fluorescence (485/505 and 535/570)
was detected with a plate reader (Infinite 200 Pro, Tecan). After measuring the basal potential, the mitochondrial uncoupler FCCP
(1 mM) was used to detect stress-induced loss of mitochondrial membrane potential, and preparations were measured until the re-
covery in the control samples was complete. Mitochondrial permeability transition pore (mPTP) opening wasmeasured by using Cal-
cein AM (1 mM, in the presence of 1 mMCoCl2; 30 min, 37C), according to the instructions. Ionomycin (500 nM) treatment was used
as positive control. Fluorescence was measured (494/517 nm) with a Tecan plate reader. Cytoplasmic and mitochondrial reactive
oxygen species (ROS) were measured by using dichlorodihydrofluorescein diacetate (DCFH-DA; 10 mM, 37C, 30 min) or MitoSOX
(200 nM, 20 min, 37C), according to the instructions. Fluorescence was measured with a plate reader (485/530 nm or 510/580 nm,
respectively). To address stress-induced ROS production and removal, preparations were treated with 1% H2O2.
Recombinant aSyn and HSP10 expression and purification
pT7-7 h aSyn and pET21A HspE1 were transformed into competent BL21 (Sigma) cells. Bacteria were incubated in 2x LB medium
at 37C with shaking to an OD600 of 0.6. Recombinant protein expression was induced with 1 mM 1-thio-b-D-galactopyranoside
(Peqlab) for 3 hours. Cells were harvested by centrifuging (6000 g, 20 min) and lysed (750 mM NaCl, 10 mM Tris, 1 mM EDTA pH
7.6, protease inhibitor (Roche, Mannheim, Germany)). The supernatant obtained after centrifugation (15 000 g, 20 min) was dialysed
(10 mM Tris pH 7.6, 1 mM EDTA, 50 mM NaCl). For purification of recombinant HSP10, the supernatant was loaded onto an anion
exchange column (HiTrap QHP, GEHealthcare) equilibrated in 25mM Tris, pH 7.6. The unbound fraction contained pure HSP10 that
was concentrated using a centrifugation filter (3K, Amicon, Merck, Darmstadt, Germany) and stored at 80C. For aSyn, the super-
natant was purified with anion exchange chromatography (HiTrap Q HP, GE Healthcare, Solingen, Germany) using a constant
gradient 0-1 mM NaCl followed by gel filtration (HiLoad Superdex 75, GE Healthcare). Pre-formed fibrils(Volpicelli-Daley et al.,
2014) and oligomers(Dio´genes et al., 2012) were prepared according to the published protocols.Cell Reports 28, 65–77.e1–e6, July 2, 2019 e4
HSP10/HSP60 protein refolding assay
HSP60/HSP10 Glow-Fold Protein Refolding Kit was used according to the manufacturer’s instructions. Briefly, recombinant aSyn
monomers, oligomers or pre-formed fibrils (PFFs) were mixed (final concentration in the reaction mixture 1 mM or 100 nM, respec-
tively) with HSP10, HSP60 and Gold-Fold substrate protein in the presence of Mg2+-ATP. The reaction mixture was incubated for
30 min, then, after 7 min heat shock (45C), luminescence was measured in the presence of Luciferin Reagent (time 0, completely
unfolded Gold-Fold substrate). The reaction mixture was further incubated at 30C, and protein folding was tested every 30 min.
In case of aSyn pretreatment, recombinant aSyn species were incubated first just with HSP10 for 30 min, then the rest of the mixture
was added, as above. Reaction mixture of the negative control did not contain Mg2+-ATP, reaction mixture of the ‘‘folding control’’
contained 0.15 mg/ml BSA instead of aSyn, the mixture of the positive control was not subjected to heat shock.
Surface-Plasmon Resonance (SPR) measurements
Interaction studies were performed by using the ProteOn XPR36 Protein Interaction Array system. Recombinant HSP10 was immo-
bilized according to manufacturer’s protocols on a GLH sensor chip by amino-coupling with a final immobilization level of 12500
RU. Analytes were diluted in PBS Tween (0.005%) as running buffer. Samples were injected with a flow rate of 50 ml/min for 2min. For
referencing a ligand surface without any bound protein was used. Data correction was done by subtracting the blank chip surface
from the protein bound surface to remove contribution of unspecific compounds on the chip surface. For obtaining the corresponding
association and dissociation rate constants the 1:1 interaction model (ProteOn analysis software) was used for fitting the
sensograms.
aSyn real time quaking-induced conversion (RT-QuiC)
RT-QuiC reactions were performed as described earlier(Orru´ et al., 2015; Groveman et al., 2018). Briefly, 100 ml of reaction mixtures
were pipetted in triplicates in black 96-well plates (Corning Incorporated, Washington, USA). The final composition of the reaction
mixtures: 150 mM NaCl, 1 mM EDTA, 10 mM ThioT, 70 mM SDS, 10 mg/ml monomeric aSyn, 1 mg/ml fibrillar aSyn in PBS buffer
(pH = 7.1), 1 mg/ml HSP10. Plates were covered with sealing tape and incubated in a plate reader (41C, Infinite M200 fluorescence
plate reader, Tecan, Hamburg, Germany) for 250 amplification cycles (1 min orbital shaking at 432 rpm; 2 min incubation; measure-
ment of fluorescence intensity at 480 nm). Endpoint fluorescent intensities were normalized by baseline values.
Proteomic screen of Syn-interacting proteins
To identify aSyn-interacting proteins, mass spectrometric analyses were performed by the Core Facility Proteomics at the University
Medical Center Go¨ttingen (Nesvizhskii et al., 2003; Atanassov and Urlaub, 2013). Synaptosome lysates from the striatum (4-5months
old BDF, Bl6, WTaSyn and A30PaSynmice) were pre-cleared and incubated in the presence of aSyn antibody (Yin et al., 2014; Szeg}o
et al., 2017). Immunoprecipitated proteins were eluted in 13 NuPAGE LDS Sample Buffer and separated on 4%–12%NuPAGE No-
vex Bis-Tris Minigels. Each lane was sliced into 23 parts, then reduced with dithiothreitol, alkylated with 2-iodoacetamide and
digested with trypsin. The resulting peptide mixtures were dried, reconstituted in 2% acetonitrile/0.1% formic acid (Atanassov
and Urlaub, 2013). Samples were enriched on a self-packed reversed phase-C18 precolumn (0.15 mm ID x 20 mm, Reprosil-
Pur120 C18-AQ 5 mm) and separated on an analytical reversed phase-C18 column (0.075 mm ID x 200 mm, Reprosil-Pur 120
C18-AQ, 3 mm) using a 15 min linear gradient of 5%–35% acetonitrile/0.1% formic acid at 300 nl/min). The eluent was analyzed
on aQ Exactive hybrid quadrupole/orbitrapmass spectrometer (Thermo Fisher Scientific) equipped with a FlexIon nanoSpray source
and operated under Excalibur 2.4 software using a data-dependent acquisitionmethod. Each experimental cycle was of the following
form: one full MS scan across the 350-1600m/z rangewas acquired at a resolution setting of 70 000 FWHM, and AGC target of 1x106
and a maximum fill time of 60 ms. Up to the 10 most abundant peptide precursors of charge states 2 to 5 above a 2x104 intensity
threshold were then sequentially isolated at 2.0 FWHM isolation width, fragmented with nitrogen at a normalized collision energy
setting of 25%, and the resulting product ion spectra recorded at a resolution setting of 17 500 FWHM, and AGC target of 2*105
and a maximum fill time of 60 ms. Selected precursor m/z values were then excluded for the following 6 s. Peaklists were extracted
from the raw data using Raw2MSMS software v1.17 (Max Planck Institute for Biochemistry, Martinsried, Germany). Protein identi-
fication was achieved using MASCOT 2.4 software (Matrixscience, London, United Kingdom). Proteins were identified against the
UniProtKB mouse reference proteome v2014.02. The search was performed with trypsin as enzyme and iodoacetamide as cysteine
blocking agent. Up to two missed tryptic cleavages and methionine oxidation as a variable modification were allowed for. Search
tolerances were set to 10 ppm for the precursor mass and 0.05 Da for fragment masses, and ESI-QUAD-TOF specified as the instru-
ment type. Scaffold software version 4.4.1.1 (Proteome Software Inc., Portland, OR) was used to validate MS/MS based peptide and
protein identifications. Peptide identifications were accepted if they could be established at greater than 95% probability by the
Percolator algorithm. Protein probabilities were assigned by the Protein Prophet algorithm (Nesvizhskii et al., 2003). Protein identi-
fications were accepted if they could be established at greater than 99% by the Percolator algorithm and contained at least 2 iden-
tified peptides. Protein hits that contained similar peptides and could not be differentiated based on MS/MS analysis alone were
grouped to satisfy the principles of parsimony. Proteins sharing significant peptide evidence were grouped into clusters.e5 Cell Reports 28, 65–77.e1–e6, July 2, 2019
Identification of HSP10 from cytoplasmic fractions by mass spectrometry
Gel electrophoreses were performed in parallel on precast NuPAGE 4%–12% Bis-Tris gradient gels using a MES buffer system
according to the manufacturer (Thermo Fisher Scientific). Proteins were either visualized by colloidal Coomassie staining (gel 1) or
transferred on nitrocellulose membranes and immunodetected as described below (gel 2). Gel regions of interest were identified
by overlaying the images fromcolloidal Coomassie staining and immunodetection in theDelta 2D image analysis software (Decodon).
Gel bands were excised manually and subjected to automated in-gel digestion with trypsin as described (Schmidt et al., 2013).
Tryptic peptides were dried down in a vacuum centrifuge, re-dissolved 0.1% trifluoro acetic acid and spiked with 2.5 fmol/mL of yeast
enolase 1 tryptic digest standard (Waters Corporation) for protein quantification according to the TOP3 method (Silva et al., 2006).
Nanoscale reversed-phase UPLC separation and ion mobility-enhanced mass spectrometric analysis of tryptic peptides was per-
formed with a Synapt G2-S QTOF LC-MS system (Waters Corporation) as described (Ott et al., 2015). A custom database was
compiled by adding the sequence information for yeast enolase 1 and porcine trypsin to the UniProtKB/Swiss-Prot mouse proteome
(UniProtKB release 2017_11, 16944 entries) and by appending the reversed sequence of each entry to enable the determination of
false discovery rate (FDR). Precursor and fragment ionmass tolerances were automatically determined by ProteinLynx Global Server
(version 3.0.2,Waters Cooperation) and were typically below 5 ppm for precursor ions and below 10 ppm (root mean square) for frag-
ment ions. Carbamidomethylation of cysteine was specified as fixed and oxidation of methionine as variable modification. One
missed trypsin cleavage was allowed. The FDR for protein identification was set to 1% threshold.
In situ Proximity Ligation Assay (PLA)
In situ PLA was performed according to manufacturer’s protocol (DuoLink PLA, Sigma-Aldrich). Briefly, PFA-fixed primary neurons
were permeabilized (0.5% Triton X-100, 10 min), blocked (2% BSA, 30 min, 37C) and incubated with the primary antibodies (anti-
HSP10 and anti-synuclein or anti-GFP and anti-synuclein). The experiment was performed with a pair of antibodies from different
species. After washing with buffer (provided in the kit), cells were incubated with the PLA probes (secondary antibodies against
two different species bound to two oligonucleotides: anti-mouse MINUS and anti-rabbit PLUS; 37C, 60 min). Ligation of the oligo-
nucleotide was performed after washing (37C, 30 min) followed by an amplification step (37C, 100 min) to label with fluorescent
oligonucleotide and increase signal intensity. For every antibody, a negative control experiment was performed where only one anti-
body was incubated with the PLA probes.
Immunostainings, microscopy, and stereology
Fixed cells or brain slices were treated according to (Szeg}o et al., 2017), and then cells were incubated in the presence of one of the
primary antibodies (see Key Resources Table, 24 h). Alexa Fluor 488, 555 or 633 (Invitrogen, Carlsbad, CA, USA) conjugated anti-
mouse, anti-rabbit or anti-rat antibodies were used. Evaluation of the number of dopaminergic neurons in the substantia nigra after
viral vector injection, was done as previously described (Szeg}o et al., 2017). Counts were performedmanually and blinded for exper-
imental grouping. After antigen retrieval (10 s formic acid, 10 min boiling in 10 mM citrate buffer; pH6) and quenching (H2O2), 6mm
paraffin sections from human brain were incubated in the presence of primary antibody (see Key Resources Table, 24 h). Alexa Fluor
488 conjugated anti-mouse (1:200) and Alexa Fluor 594 conjugated anti rabbit (1:200) antibodies were used for 1 h. Fluorescent im-
ages were taken using an Olympus IX81-ZDC microscope with Excellence software. Exposure time was equal for the same staining
across the experimental groups. Manders’ coefficient was calculated by using ImageJ JACoP plugin. For confocal imaging, human
brains were fixed (6%PFA, 1month) and cryoprotected (20% sucrose). Regions were cut into coronal whole brain sections and small
specimens. Basal ganglia and mesencephalon were separated cut into 40 mm thick sections. After washing and blocking (1% BSA,
5% normal donkey serum and 0.3% Triton X-100), free-floating sections were incubated first with primary antibodies (HSP10, Santa
Cruz and aSyn, Santa Cruz; overnight, 4C), then with fluorescence conjugated secondary antibodies (anti-mouse Alexa Fluor 488
and anti-rabbit Cy3 (Invitrogen), 2 h, room temperature). Fluorescent images were taken using an Olympus DP73 camera, driven by
CellSens software. Confocal images were taken using Leica SP8 camera driven by Leica Application Suite X software.
QUANTIFICATION AND STATISTICAL ANALYSIS
Selection of animals or distribution of conditions in each experiment was randomized. Data collection was done blinded. Data was
assessed for normality using the Shapiro–Wilk test, for equal variance using F test. Data were analyzed either with 1- or 2-way anal-
ysis of variance followed by Tukey’s honestly significant difference test (Statistica, StatSoft, Tulsa, USA). % change in the SRC was
analyzed after normalization, the individual animal and experimental numbers were used as random factor (Szeg}o et al., 2012). The
null hypothesis was rejected at the 0.05 p value level. Data are presented as mean ± SD.
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